Anatabine (Tobacco Pyridine Alkaloid · Anti-inflammatory · STAT3 Inhibitor · Anatabloc)

Compound	Anatabine
Chemical class	Alkaloid — Pyridine-Pyrrolidine (bis-pyridyl; tobacco minor alkaloid)
CAS	581-49-7
Primary source	Nicotiana tabacum (tobacco leaves, minor alkaloid ~1–3% of total alkaloid fraction)
Key applications	Anti-inflammatory (NF-κB / STAT3), neurological research, thyroid health; availability on request
Claim strength	Moderate (preclinical); limited human
Typical form	Not commercially established at supplement scale; anatabine isolate (former StarScientific ingredient)
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Nicotiana tabacum (anatabine — a minor tobacco alkaloid). Anatabine is a bis-pyridyl alkaloid — two pyridine rings, one saturated (partially) — structurally simpler than nicotine (no pyrrolidine methyl group). It occurs naturally in tobacco alongside nicotine (the major alkaloid), nornicotine, anabasine, and cotinine. Research trajectory: Anatabine attracted significant commercial and research interest in 2010–2013 when it was marketed as a dietary supplement (Rock Creek Pharmaceuticals — a Star Scientific subsidiary) under the brand name “Anatabloc” for inflammation management. Clinical claims included anti-inflammatory benefits (NF-κB and STAT3 inhibition) with particular interest in thyroid conditions and neurodegenerative disease. The supplement was withdrawn in 2014 after Star Scientific’s CEO resigned amid a political scandal, and the FTC challenged marketing claims. Independent clinical evidence for anatabine remains limited — animal models are compelling but adequately powered human trials were not completed. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.

---

Evidence for Anatabine Applications

Anti-inflammatory via NF-κB and STAT3 inhibition: Anatabine potently inhibits STAT3 phosphorylation and NF-κB activity in macrophage and neural cell models at low micromolar concentrations. In transgenic Alzheimer’s mouse models, anatabine reduced neuroinflammation and amyloid-beta burden. The dual NF-κB/STAT3 inhibition profile is pharmacologically interesting and differentiates anatabine from simpler anti-inflammatory compounds. Claim strength: Moderate (preclinical convergent; limited human).

Thyroid health and Hashimoto’s research: A small pilot study (n=14, Benowitz et al. referenced in Anatabloc literature) suggested anatabine supplementation reduced thyroglobulin antibodies in patients with autoimmune thyroiditis (Hashimoto’s). If confirmed, this would represent a novel botanical approach to autoimmune thyroid disease. The study was small and methodologically limited; no independent replication has been published. Claim strength: Emerging (single small study; no replication).

Nicotinic receptor activity: Anatabine is a nicotinic acetylcholine receptor partial agonist (similar to anabasine), which may contribute to its anti-inflammatory effects via the “cholinergic anti-inflammatory pathway” (vagal nerve → α7-nAChR → NF-κB suppression in macrophages). Claim strength: Moderate (mechanism established in cholinergic anti-inflammatory literature).

---

Dosage & Formulator Specification

Anatabloc supplement (historical): 1 mg anatabine per tablet, 2–4 tablets/day (2–4 mg/day). The marketed product was withdrawn before controlled efficacy data were published. Based on animal model extrapolation, 1–10 mg/day anatabine is the studied range. Contact Herbuno for anatabine extract availability and specification.

---

Frequently Asked Questions — Anatabine

What happened to Anatabloc?
Anatabloc (anatabine supplement) was marketed by Rock Creek Pharmaceuticals from ~2011, targeting inflammation management and neurodegeneration. The FTC challenged the marketing claims in 2014 for insufficient evidence, and the product was withdrawn after the parent company Star Scientific faced an unrelated corporate governance scandal. The withdrawal was not primarily due to safety concerns but to the combination of regulatory pressure and corporate disruption. The underlying science (STAT3/NF-κB inhibition) remains published and scientifically interesting.

Is anatabine addictive like nicotine?
Anatabine has nicotinic receptor activity but is a weaker nAChR agonist than nicotine, with lower addiction potential. In the Anatabloc supplement era, no significant addiction or abuse potential was documented in users at marketed doses (1–4 mg/day). However, as a tobacco-derived minor alkaloid with nicotinic activity, anatabine should be treated with appropriate caution regarding dependence potential at higher doses.

Can anatabine be extracted from tobacco?
Technically yes — anatabine is present at approximately 1–3% of the total alkaloid fraction in tobacco (relative to nicotine at ~90%). However, tobacco extraction for supplement purposes creates significant regulatory complexity — the resulting extract would be classified as a tobacco product in most markets, not as a botanical supplement. Synthetic anatabine is a more commercially practical source for any research or supplement application.

What is the current research status of anatabine for Alzheimer’s?
Academic research continues in animal models and cell lines following the publication of promising Alzheimer’s mouse model data. No human clinical trials for anatabine in Alzheimer’s have been completed or reported. The commercial momentum from the Anatabloc era has not been re-established since the 2014 withdrawal, leaving an interesting preclinical profile without a clinical development programme to drive it forward.

Related compounds: Nicotine, Lobeline, Anabasine, Vasicinone

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery